ZFYVE9

Across TCGA pan-cancer cohorts, ZFYVE9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZFYVE9 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZFYVE9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZFYVE9 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where ZFYVE9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.889	0.588	.001	47	view →
LUAD	DFS	Median	III,IV	0.550	0.931	.008	27	view →
LSCC	OS	Median	III,IV	0.919	0.571	.017	7	view →
HNSC	OS	Median	IV	0.609	0.838	.028	4	view →
CCRCC	DFS	Median	III,IV	1.000	0.451	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZFYVE9–PDAC (DFS)

Open the PDAC breakdown →